-The Indian Express Attitudes toward climate change in India can appear paradoxical. Although India is one of the countries most deeply vulnerable to climate impacts, climate change does not rank high on policymakers' list of concerns. Two factors explain this inattention. First, India has pressing and immediate development concerns, such as providing sanitation, improved healthcare and access to affordable energy to its population, while the effects of climate change appear abstract...

-Livemint NHAM aims to provide all citizens with free drugs and diagnostic treatment, as well as insurance cover to treat serious ailments New Delhi: India's universal health plan that aims to offer guaranteed benefits to a sixth of the world's population will cost an estimated Rs1.6 trillion ($26 billion) over the next four years, a senior health ministry official said. Under the National Health Assurance Mission (NHAM), Prime Minister Narendra Modi's government...

-Tehelka Despite the serious toll it takes on women's health, female sterilisation remains the most prevalent form of contraception in India. While memories of the 21 months of Emergency in 1975-77, imposed by the then prime minister Indira Gandhi, survives even today in the minds of Indian men as the fear of forced sterilisation, the country's population control policies have shifted over the years since then to target the politically less...

-UNDP India New Delhi: "Social media is changing the way we live and relate to each other" said noted filmmaker Shekhar Kapur. The challenge in his view, was "how to ensure those ideas are positive and for the good?" Mr. Kapur was speaking at the Social Good Summit 2014, ‘Technology for Social Good' organized by the United Nations Development Programme in India. Talking of his vision for the world in 2030,...

-The Business Standard A ray of hope for Indian generic drug makers Gilead Sciences, the California-headquartered biotechnology company, has authorised seven India-based drug makers - Cipla, Ranbaxy, Mylan, Strides Arcolab, Hetero, Cadila Healthcare and Sequent Scientific - to manufacture and sell the generic versions of its hepatitis C medicine, Sovaldi, in 91 developing countries. Earlier in the week, Lupin, the fourth largest Indian drug maker, announced that it will develop and supply...